Morgan Stanley raised its target for Cardinal Health and kept its Buy rating, showing a more favorable view from the firm. The report gives no new company results, so the support comes from one analyst's opinion.
That gives investors a more favorable outside view of Cardinal Health. The report offers no new sales, profit, or company forecast, so the change rests on one analyst's opinion rather than fresh company results.
Follow Cardinal Health, Inc. (CAH) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CAH